Recent

% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

  • homebuilder_watcher homebuilder_watcher Mar 6, 2013 8:34 AM Flag

    Interesting note from Leerink this morning

    "Given numerous approaching Vosaroxin catalysts not reflected in our current model and $10 valuation, we begin a multiple part series exploring upside to our valuation possibly driven by these catalysts. We start with a 2Q13 LI-1 trial front line (FL) AML update that will suggest whether Vosaroxin could become a meaningful FL therapy....If either arm proceeds to Stage-2, this would significantly de-risk potential FL approval and lead us to increase our valuation to $16. For now, we reiterate our Outperform rating and $10 valuation on SNSS.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SNSS
3.01+0.16(+5.61%)Jun 30 4:00 PMEDT